幽门螺杆菌根除后胃非贲门腺癌的风险
这项基于北欧五国人群的队列研究纳入1995至2019年间接受幽门螺杆菌根除治疗的659,592名成人,比较其胃非贲门腺癌发病率与背景人群。治疗后1-5年标准化发病比(SIR)为2.27(95%CI 2.10-2.44),此后逐渐下降,11-24年降至1.11(95%CI 0.98-1.27),接近背景人群水平。
要点
- 根除治疗后1-5年胃非贲门腺癌风险仍高于背景人群,SIR为2.27。
- 风险随时间逐渐下降,11-24年SIR为1.11,接近背景人群水平。
- 研究纳入北欧五国659,592名接受根除治疗的成人,随访至24年。
核心结论
- 在5个西方人群中,幽门螺杆菌根除治疗后胃非贲门腺癌发病率随时间下降,自治疗后11年起风险与背景人群基本相似。
研究设计与样本
- 基于人群的队列研究,纳入1995至2019年间在丹麦、芬兰、冰岛、挪威和瑞典任一国家接受幽门螺杆菌根除治疗的所有成人。
- 共659,592名参与者,贡献5,480,873人年风险随访,其中1311人发生胃非贲门腺癌。
- 通过比较研究队列与相同年龄、性别、日历时期和国家的背景人群的胃非贲门腺癌发病率,计算标准化发病比(SIR)及95%置信区间(CI)。
- 采用泊松回归评估SIR的时间趋势。
主要发现
- 随访至24年,治疗后1-5年SIR为2.27(95%CI 2.10-2.44),高于背景人群。
- SIR随时间逐渐下降,治疗后11-24年SIR为1.11(95%CI 0.98-1.27),接近背景人群水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Helicobacter pylori infection of the stomach is the main risk factor for gastric noncardia adenocarcinoma; however, less is known on how eradication of H pylori influences the risk of this tumor over time, particularly in Western populations. The aim of this study was to delineate how the risk of gastric noncardia adenocarcinoma develops over time after H pylori eradication treatment in a Western population compared with the background population. METHODS: This population-based cohort study included all adults having received H pylori eradication treatment between 1995 and 2019 in any of the Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden). Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were calculated by comparing the gastric noncardia adenocarcinoma incidence in the study cohort with the incidence in the background population of the same age, sex, calendar period, and country. Time trends in SIR were assessed using Poisson regression. RESULTS: Among 659,592 participants having received H pylori eradication treatment, contributing 5,480,873 person-years at risk, 1311 developed gastric noncardia adenocarcinoma. During up to 24 years of follow-up, the SIR was initially higher than the background population (SIR, 2.27; 95% CI 2.10-2.44, 1-5 years after treatment), and then gradually decreased over time and approached the level of the background population from 11 years after treatment (SIR, 1.11; 95% CI 0.98-1.27, 11-24 years after treatment). CONCLUSION: This study revealed a decreasing incidence of gastric noncardia adenocarcinoma after H pylori eradication treatment in 5 Western populations. The risk became virtually similar to the background population from 11 years after treatment.
引用
- Wiklund AK, Santoni G, Yan J, et al. Risk of Gastric Adenocarcinoma After Eradication of Helicobacter pylori. Gastroenterology. 2025. PMID: 39924057. doi:10.1053/j.gastro.2025.01.239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。